TEVA
NYSETeva Pharmaceutical Industries Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$31.20+0.31 (+1.00%)
01:30 PM07:45 PM
News · 26 weeks86-88%
2025-10-262026-04-19
Mix5390d
- Insider37(70%)
- Other8(15%)
- SEC Filings5(9%)
- Earnings3(6%)
Latest news
25 items- PRTeva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care PartnersFor people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer-driven insights, tools and connection Home Ground™ was developed in collaboration with people living with schizophrenia, care partners and mental health advocacy groups to help support wellbeing through shared experienceAs a leader in neuroscience, Teva is committed to supporting people living with complex mental health conditions through practical resources to help navigate the care journey PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceu
- SECSEC Form DEFA14A filed by Teva Pharmaceutical Industries LimitedDEFA14A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- SECSEC Form DEF 14A filed by Teva Pharmaceutical Industries LimitedDEF 14A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- PRTeva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)Teva's biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva's proposed biosimilar candidate to Xolair® (omalizumab) is accepted for review by U.S. FDA and EU EMA.These milestones demonstrate Teva's biosimilars expertise and are a significant step in Teva's Pivot to Growth strategy, highlighting its transformation into a leading biopharmaceutical company with a broad biosimilars portfolio. TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfo
- PRTeva Releases Q1 2026 Aide MemoireTEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indust
- PRTeva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be
- INSIDERSEC Form 4 filed by Sabag Mark4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Sabag Mark converted options into 15,723 units of Ordinary Shares, increasing direct ownership by 6% to 287,042 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Chief Financial Officer Kalif Eliyahu Sharon converted options into 19,916 units of Ordinary Shares, increasing direct ownership by 7% to 325,435 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERChief Accounting Officer Weiss Amir converted options into 3,537 units of Ordinary Shares, increasing direct ownership by 13% to 30,695 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERPresident and CEO Francis Richard D converted options into 42,452 units of Ordinary Shares and sold $634,160 worth of Ordinary Shares (20,025 units at $31.67), increasing direct ownership by 2% to 1,170,639 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, U.S. Commercial Fox Christine converted options into 17,819 units of Ordinary Shares and sold $250,940 worth of Ordinary Shares (7,924 units at $31.67), increasing direct ownership by 13% to 84,905 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Hughes Eric A sold $301,895 worth of Ordinary Shares (9,533 units at $31.67) and converted options into 19,654 units of Ordinary Shares, increasing direct ownership by 10% to 107,711 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Europe Commercial Daniell Richard sold $547,705 worth of Ordinary Shares (17,295 units at $31.67) and converted options into 17,295 units of Ordinary Shares (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Jover Placid converted options into 14,150 units of Ordinary Shares and sold $448,108 worth of Ordinary Shares (14,150 units at $31.67) (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERInterim Chief Legal Officer Savage Brian converted options into 3,580 units of Ordinary Shares and sold $35,690 worth of Ordinary Shares (1,127 units at $31.67), increasing direct ownership by 29% to 10,914 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Global Operations Shields Matthew converted options into 17,295 units of Ordinary Shares and sold $547,705 worth of Ordinary Shares (17,295 units at $31.67) (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERPresident and CEO Francis Richard D converted options into 50,223 units of Ordinary Shares and sold $759,442 worth of Ordinary Shares (23,393 units at $32.46), increasing direct ownership by 2% to 1,148,212 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Europe Commercial Daniell Richard converted options into 53,973 units of Ordinary Shares and sold $2,983,517 worth of Ordinary Shares (91,345 units at $32.66), decreasing direct ownership by 30% to 85,755 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by See "Remarks" Jover Placid4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Global Operations Shields Matthew4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Sabag Mark converted options into 52,113 units of Ordinary Shares, increasing direct ownership by 24% to 271,319 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Business Development Lippman Evan4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Hughes Eric A converted options into 23,251 units of Ordinary Shares and sold $366,102 worth of Ordinary Shares (11,277 units at $32.46), increasing direct ownership by 14% to 97,590 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Chief Financial Officer Kalif Eliyahu Sharon converted options into 56,763 units of Ordinary Shares, increasing direct ownership by 23% to 305,519 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)